Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues

doi:10.3748/wjg.v20.i24.7686

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 20, Issue 24

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (6385)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-4) series.

Item

Count

PDF

435

WORD

237

HTML

3689

Tables (1-4)

185

Sum=4546

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

891

Download

948

Sum=1839

Jun 28, 2014 (publication date) through Sep 26, 2024

Times Cited of This Article

Times Cited (24)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Topic Highlight

World J Gastroenterol. Jun 28, 2014; 20(24): 7686-7695
Published online Jun 28, 2014. doi: 10.3748/wjg.v20.i24.7686

Table 1 Comparison of hepatitis B surface antigen kinetic between interferon and nucleos(t)ide analogues

Interferon vs NA	HBeAg status	Mean decline of HBsAg (log IU/mL) at week 48		Ref.
Peginterferon alfa-2a + lamivudine vs lamivudine	HBeAg (-) patients	0.71 vs 0.02	P < 0.001	[13]
Peginterferon alfa-2a vs lamivudine alone	HBeAg (-) patients	0.67 vs 0.02	P < 0.001	[13]
Peginterferon vs entecavir	HBeAg (+) patients	0.94 vs 0.38	P = 0.07	[26]
	HBeAg (-) patients	0.56 vs -0.10	P < 0.001	[26]

NAs: Nucleos(t)ide analogues; HBsAg: Hepatitis B surface antigen; HBeAg: Hepatitis B e antigen.

Citation: Chen CH, Chiu YC, Lu SN, Lee CM, Wang JH, Hu TH, Hung CH. Serum hepatitis B surface antigen levels predict treatment response to nucleos(t)ide analogues. World J Gastroenterol 2014; 20(24): 7686-7695
URL: https://www.wjgnet.com/1007-9327/full/v20/i24/7686.htm
DOI: https://dx.doi.org/10.3748/wjg.v20.i24.7686